Canada markets open in 29 minutes

Aclaris Therapeutics, Inc. (8AT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.1150+0.0110 (+1.00%)
As of 08:02AM CEST. Market open.
Full screen
Previous Close1.1040
Open1.1150
Bid1.1140 x 0
Ask1.1820 x 0
Day's Range1.1150 - 1.1150
52 Week Range0.5900 - 11.8450
Volume2,820
Avg. Volume1,055
Market Cap82.925M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

    WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update. “As we enter 2024, we are financially strong, focused and motivated,” stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. “Returnin

  • GlobeNewswire

    Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

    - Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced leadership changes and that it is undertaking a strategic review o

  • GlobeNewswire

    Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

    - ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an i